Carcinoid News (1 article)
Phase III Novartis data show potential benefit of Afinitor® plus Sandostatin® LAR® in patients with advanced neuroendocrine tumors
Everolimus plus octreotide LAR extended time without tumor growth from 11.3 to 16.4 months versus octreotide LAR alone in advanced NET (carcinoid) patients The study did not reach its primary endpoint of progression-free survival Analyses to adjust for imbalances in...
Published on 11 October 2010, 08:28
We have launched our peer- reviewed, Open-access journal: Insciences Journal